SciSparc (SPRC) Research & Development (2016 - 2022)

SciSparc (SPRC) posted Research & Development of $659000.0 for Q4 2022, down 1.64% sequentially from $670000.0 in Q3 2022.

SciSparc (SPRC) Research & Development (2016 - 2022) Analysis & Trends

SciSparc has reported Research & Development for 5 years, with the latest figure at $659000.0 in Q4 2022.

Quarterly Research & Development changed N/A year-over-year to $659000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1.8 million (changed N/A YoY) and the FY2025 annual result came in at $2.1 million, up 22.85% from the prior year.
Research & Development slipped to $659000.0 in Q4 2022 per SPRC's latest filing, from $670000.0 in the prior quarter.
Over five years, Research & Development peaked at $995000.0 in Q1 2018 and troughed at $245000.0 in Q1 2019.
A 3-year average of $567250.0 and a median of $654500.0 in 2018 frame the typical range for Research & Development.
The sharpest annual moves came in 2018 and 2019: Research & Development surged 314.58% in 2018, then plunged 75.38% in 2019.
Over 3 years, Research & Development stood at $366000.0 in 2018, then slumped by 30.6% to $254000.0 in 2019, then soared by 159.45% to $659000.0 in 2022.
According to Business Quant data, Research & Development over the past three periods registered $659000.0, $670000.0, and $254000.0 for Q4 2022, Q3 2022, and Q2 2019 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	R&D (Qtr)
1	Vertex Pharmaceuticals	140.29 Bn	132.43 Bn	2.84 Bn	993.80 Mn
2	Regeneron Pharmaceuticals	86.58 Bn	78.58 Bn	3.93 Bn	1.63 Bn
3	Argenx Se	65.26 Bn	60.08 Bn	1.37 Bn	1.37 Bn
4	Moderna	61.87 Bn	56.73 Bn	52.00 Mn	651.00 Mn
5	BeOne Medicines	42.18 Bn	37.08 Bn	1.53 Bn	612.28 Mn
6	Alnylam Pharmaceuticals	31.51 Bn	28.20 Bn	992.69 Mn	413.13 Mn
7	BioNTech SE	28.90 Bn	10.51 Bn	668.28 Mn	-588.31 Mn
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn	210.03 Mn
9	Royalty Pharma	27.24 Bn	26.41 Bn	-	97.90 Mn
10	SciSparc	807,202.50	807,202.50	-	-

Download Data